BAISHIDENG PUBLISHING GROUP INC
8226 Regency Drive, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242 Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

Name of Journal: *World Journal of Hepatology*

ESPS Manuscript NO: 28671

Manuscript Type: Original Article

Dear Editor,

Please find enclosed the edited manuscript in word format (file name: 28671-Revised Manuscript).

Title: Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis

Author: Yuichi Torisu, Masanori Nakano, Keiko Takano, Ryo Nakagawa, Chisato Saeki, Atsushi Hokari, Tomohisa Ishikawa, Masayuki Saruta, Mikio Zeniya

Name of Journal: *World Journal of Hepatology*

ESPS Manuscript NO: 28671

The manuscript has been improved according to the suggestions of reviewers. The part written in underline is revised in the new manuscript.

To Reviewer 02861055, thank you for your kindly review.

Reviewer`s comments

1. The Authors should clarify which patients treated with UDCA.

2. The Authors should specify if cases of AIH-primary biliary cholangitis and AIH-primary sclerosing cholangitis variants have been ruled out.

3. The main limitation of the study is that the Authors do not show an appropriate control group for the UDCA-treated patients. The latter appears to be a group of patients with a mild disease for which indication for standard treatment is currently uncertain. This aspect should be better discussed by the Authors.

4. Duration of follow-up should be included.

5. Data about the efficacy of prednisolone treatment in inducing remission should also be added.

Answer

1. According to your suggestion, the clinical characteristics of patients received UDCA monotherapy have been added to MATERIALS AND METHODS (Pages 10, underlined sentences).

2. In this analysis, we had excluded the cases of AIH-primary biliary cholangitis and AIH-primary sclerosing cholangitis variants. So, we added as excluded patients (Pages 9, underlined sentences).

3. According to your suggestion, we discussed about this point (Pages 14-15, underlined sentences).

4. Duration of follow-up has been added to RESULT (Pages 12, underlined sentences).

5. Data about the efficacy of prednisolone treatment has been added to RESULT (Pages 12, underlined sentences).

To Reviewer 01801241, thank you for your kindly review.

Reviewer`s comments

1. Core tip: the results suggest that..this must be confirmed in a prospective study.

2. They do not explain why a group of pastients (what clinical characteristics) only

received UDCA. M&Methods: explain, if known, why the 48 patients are included in the U group, only UDCA. Less severe clinical cases for the clinicians?

3. Why they use a dosage of 600 mg/d, and not 15 mg/kg/day as in PBC? M&Methods: explain why 600mg dosage.

4. UDCA should be considered... better may be? can be?. Future studies...prospective studies.

Answer

1. According to your suggestion, we added this sentence in Core tip (Pages 5, underlined sentences).

2. We have been added the clinical characteristics of patients received UDCA monotherapy to MATERIALS AND METHODS (Pages 10, underlined sentences).

3. In Japanese guideline for the treatment of PBC, 600 mg/day (10-13 mg/kg/day) is recommended as initial therapeutic dose of UDCA. This point has been added to MATERIALS AND METHODS (Pages 10, underlined sentences).

4. According to your suggestion, we have changed the sentence (Pages 16, underlined sentences).

Thank you again for your comments on our manuscript. We believe that the revised manuscript is suitable for publication.